Non-Fucosylated Anti-Human CD20 (BLX-300) Therapeutic Antibody (CAT#: BioBet-1783ZP) Datasheet

MS4A1

membrane spanning 4-domains A1

This gene encodes a member of the membrane-spanning 4A gene family. Members of this nascent protein family are characterized by common structural features and similar intron/exon splice boundaries and display unique expression patterns among hematopoietic cells and nonlymphoid tissues. This gene encodes a B-lymphocyte surface molecule which plays a role in the development and differentiation of B-cells into plasma cells. This family member is localized to 11q12, among a cluster of family members. Alternative splicing of this gene results in two transcript variants which encode the same protein.

B1; S7; Bp35; CD20; CVID5; MS4A2; LEU-16

Protein Based Therapies
Monoclonal antibody (mAb)

IgG4, bispecific

BLX-300 (Rituximab)

Humanized

Human

This clone was generated using a stable CHO cell line with the FUT8 knockout gene. It was 100% non-fucosylated. In an in vitro cell-based ADCC assay, the afucosylated antibody clone showed significantly higher ADCC activity compared to its wild type version. The binding affinity of the non-fucosylated Fc variant antibody to Fc receptor is much higher than than the same antibody with fucosylated Fc. Robust and stable production of qualitative fully non-fucosylated therapeutic antibodies is achieved.